Abstract
The therapeutic potential of human mesenchymal stromal stem cells (hMSCs) for cell-based therapeutic is greatly influenced by the in vitro culture condition including the culture conditions. Nevertheless, there are many technical challenges needed to be overcome prior to the clinical use including the quantity, quality, and heterogeneity of the cells. Therefore, it is necessary to develop a stem cell culture procedure or protocol for cell expansion in order to generate reproducible and high-quality cells in accordance with good manufacturing practice for clinical and therapeutic purposes. Here we assessed the MSCs characteristic of human Wharton’s jelly mesenchymal stromal cells in in vitro culture according to the criteria established by the International Society for Cellular Therapy. Besides, the viability of the WJMSCs was determined in order to increase the confidence that the cells are employed to meet the therapeutic efficacy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Heathman TR, Nienow AW, McCall MJ, Coopman K, Kara B, Hewitt CJ (2015) The translation of cell-based therapies: clinical landscape and manufacturing challenges. Regen Med 10:49–64
Buzhor E, Leshansky L, Blumenthal J, Barash H, Warshawsky D, Mazor Y, Shtrichman R (2014) Cell-based therapy approaches: the hope for incurable diseases. Regen Med 9:649–672
Wei X, Yang X, Han ZP, Qu FF, Shao L, Shi YF (2013) Mesenchymal stem cells: a new trend for cell therapy. Acta Pharmacol Sin 34:747–754
Kalaszczynska I, Ferdyn K (2015) Wharton’s jelly derived mesenchymal stem cells: future of regenerative medicine? Recent findings and clinical significance. Biomed Res Int 2015:430847
Batsali AK, Kastrinaki MC, Papadaki HA, Pontikoglou C (2013) Mesenchymal stem cells derived from Wharton’s Jelly of the umbilical cord: biological properties and emerging clinical applications. Curr Stem Cell Res Ther 8:144–155
Galipeau J, Sensebe L (2018) Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell 22:824–833
Trounson A, McDonald C (2015) Stem cell therapies in clinical trials: progress and challenges. Cell Stem Cell 17:11–22
Sepulveda JC, Tome M, Fernandez ME, Delgado M, Campisi J, Bernad A, Gonzalez MA (2014) Cell senescence abrogates the therapeutic potential of human mesenchymal stem cells in the lethal endotoxemia model. Stem Cells 32:1865–1877
Wagner W, Horn P, Castoldi M, Diehlmann A, Bork S, Saffrich R, Benes V, Blake J, Pfister S, Eckstein V et al (2008) Replicative senescence of mesenchymal stem cells: a continuous and organized process. PLoS One 3:e2213
Wagner W, Ho AD, Zenke M (2010) Different facets of aging in human mesenchymal stem cells. Tissue Eng Part B Rev 16:445–453
Wagner W, Bork S, Lepperdinger G, Joussen S, Ma N, Strunk D, Koch C (2010) How to track cellular aging of mesenchymal stromal cells? Aging 2:224–230
Hayflick L (1965) The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 37:614–636
Wagner W, Bork S, Horn P, Krunic D, Walenda T, Diehlmann A, Benes V, Blake J, Huber FX, Eckstein V et al (2009) Aging and replicative senescence have related effects on human stem and progenitor cells. PLoS One 4:e5846
Turinetto V, Vitale E, Giachino C (2016) Senescence in human mesenchymal stem cells: functional changes and implications in stem cell-based therapy. Int J Mol Sci 17(7)
Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8:315–317
Kurz DJ, Decary S, Hong Y, Erusalimsky JD (2000) Senescence-associated (beta)-galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells. J Cell Sci 113:3613–3622
Acknowledgments
This research was supported by High Impact Research MOHE Grant UM.C/625/1/HIR/MOHE/DENT/01 from Ministry of Higher Education Malaysia, Fundamental Research Grant Scheme (FRGS FP044-2014B) from Ministry of Education, Malaysia, and University of Malaya Research Grant (RP019C-13HTM) from University of Malaya.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media New York
About this protocol
Cite this protocol
Aung, SW., Abu Kasim, N.H., Ramasamy, T.S. (2019). Isolation, Expansion, and Characterization of Wharton’s Jelly-Derived Mesenchymal Stromal Cell: Method to Identify Functional Passages for Experiments. In: Turksen, K. (eds) Stem Cells and Aging . Methods in Molecular Biology, vol 2045. Humana, New York, NY. https://doi.org/10.1007/7651_2019_242
Download citation
DOI: https://doi.org/10.1007/7651_2019_242
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-4939-9712-1
Online ISBN: 978-1-4939-9713-8
eBook Packages: Springer Protocols